Our results suggest oral, commonly used antiplatelet therapy with aspirin and P2Y12 antagonism improves stroke outcomes in hPAR4Ala/Ala mice, but not hPAR4Thr/Thr mice, and causes more brain bleeding in the latter. Here, P2RY12 is linked to stroke disorder.